#AVCT

POINT Hierachy has moved to AdvanCell.

Matthew Vincent being the key deal maker with Bachovchin for the canSEEK tech. Now AdvanCell’s CBO.

#AVCT

Context.

#AVCT

“Disgustingly cheap”

$VRTX enters into agreement to acquire Alpine Immune Sciences $ALPN for $65 per share or ~$4.9B in cash

Easy to forget #AVCT was never meant to continue dose escalating, they were never meant to see deep, meaningful efficacious responses in a heavily pre-treated patient population.

This ‘safety’ trial talks to efficacy because this heavily pre-treated, very sick, patient

#AVCT

The PKs are more informing than the AEs. A SIGNIFICANT reduction in free dox exposure. Why?

The AEs *should* improve with more healthy patients, and those with FAPhigh tumours.

The free dox exposure variable is here to stay.

💉 5x LESS free dox than Aldoxorubicin.

Our presentation at #AACR24 today - well received with many intriguing conversations.

Grateful and humbled by our lead author Prof udaibanerji who did not stop speaking for 3.5 hours. Udai - much appreciated

#PeptidesCreateHope
#LetsDoThis

The Royal Marsden NHS Foundation Trust The ICR

#AVCT

Above all, FAP clips dox. Dox kills.

Platform is ‘further validated’. The substrate sells. Unequivocally.

#AVCT

Christina Coughlin is very good. Avacta is maturing overnight with her delivering quality, directed messaging on the *platform*. It’s night and day.

🎯 Additional approaches: Platform.
🎯 Antibody: Biologic agnostic.
🎯 Approaches in clinic: Partnerships.

ICR Consilium

Now Online Fibroblast and myofibroblast activation in normal tissue repair and fibrosis dlvr.it/T5FQMp

Easier to get a ticket for a Taylor Swift concert than to find a seat at the #AACR24 Next Generation ADC session!

#AVCT

I suspect tumours high in FAP (known?) have been selected in C7 and Q2W. This data I’m looking forward to.

#AVCT

Bet this is an interesting presentation & study.

Almost guaranteed that Avacta ‘s FAP activated prodrug, #AVA6000 gets a mention.

#AVCT

Interesting article.

“Our real focus right now is the tumour and the tumour micro environment”

“Which can make up to 90% of the tumour mass”

Yet more focus and language about the stroma.

#AVCT

There’s a reason they’re protecting that key.

#AVCT

“The key target is the stroma itself”

FAP is not an appreciated target as there is little evidence, in the clinical setting, to suggest otherwise.

Disconnect kinda makes sense. Until such clinical evidence presents itself in such a way.

#AVCT

Looking forward to the day when we are talking about a product in the market rather than the pantomime this feed is at the moment.

Research while we wait.

To me. To you.